Merck & Co Inc., of Whitehouse Station, N.J., said it expects the FDA to issue a complete response letter for its new drug application for sugammadex, a medicine to reverse the effects of anesthesia, after the agency canceled the March 18 meeting of the Anesthetic and Analgesic Drug Products Advisory Committee, which was scheduled to discuss the resubmitted application.